Mozavaptan

Mozavaptan
	File:Mozavaptan structure.svg
Systematic (IUPAC) name
	N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
Clinical data
Legal status	℞ (Prescription only);
Routes of; administration	Oral
Identifiers
CAS Number	137975-06-5
ATC code	none
PubChem	CID: 119369
IUPHAR/BPS	2197
ChemSpider	106618
UNII	17OJ42922Y
ChEMBL	CHEMBL420762
Chemical data
Formula	C27H29N3O2
Molecular mass	427.53 g/mol
	SMILES CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C ;
	InChI InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) ; Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N ;
(what is this?) (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.